Equities Analysts Issue Forecasts for Veru Inc.’s Q3 2024 Earnings (NASDAQ:VERU)

Veru Inc. (NASDAQ:VERUFree Report) – Investment analysts at B. Riley issued their Q3 2024 earnings per share estimates for Veru in a report issued on Monday, May 13th. B. Riley analyst W. Wood anticipates that the company will post earnings of ($0.05) per share for the quarter. B. Riley currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Veru’s current full-year earnings is ($0.26) per share. B. Riley also issued estimates for Veru’s Q4 2024 earnings at ($0.08) EPS, FY2024 earnings at ($0.26) EPS and FY2025 earnings at ($0.31) EPS.

Veru (NASDAQ:VERUGet Free Report) last posted its quarterly earnings results on Monday, April 1st. The company reported ($0.09) earnings per share for the quarter. The company had revenue of $2.14 million for the quarter. Veru had a negative return on equity of 130.13% and a negative net margin of 265.27%.

Several other research firms have also weighed in on VERU. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Veru in a research note on Monday. Raymond James started coverage on Veru in a research report on Thursday, March 28th. They set an “outperform” rating and a $3.00 price target on the stock. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $5.00 price objective (down from $7.00) on shares of Veru in a research report on Monday, April 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Veru presently has a consensus rating of “Moderate Buy” and an average price target of $4.00.

Read Our Latest Stock Analysis on VERU

Veru Stock Performance

NASDAQ VERU opened at $1.47 on Thursday. The firm has a market capitalization of $215.18 million, a P/E ratio of -4.32 and a beta of -0.47. The firm’s fifty day moving average price is $1.07 and its two-hundred day moving average price is $0.83. Veru has a 1 year low of $0.36 and a 1 year high of $1.92.

Institutional Trading of Veru

Several hedge funds and other institutional investors have recently modified their holdings of VERU. Worth Venture Partners LLC acquired a new stake in Veru during the fourth quarter worth approximately $616,000. AIGH Capital Management LLC bought a new position in shares of Veru during the fourth quarter worth approximately $2,476,000. ADAR1 Capital Management LLC acquired a new stake in Veru during the 4th quarter worth approximately $360,000. Octagon Capital Advisors LP bought a new stake in Veru in the 4th quarter valued at $2,736,000. Finally, Perceptive Advisors LLC grew its holdings in Veru by 412.4% in the 4th quarter. Perceptive Advisors LLC now owns 5,584,699 shares of the company’s stock valued at $4,021,000 after buying an additional 4,494,821 shares in the last quarter. Institutional investors own 47.16% of the company’s stock.

About Veru

(Get Free Report)

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

Read More

Earnings History and Estimates for Veru (NASDAQ:VERU)

Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.